News

New Brain Tumor Clinical Trials: January – June 2022 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the […] July 5, 2022

New Treatment Approved for Certain Glioma Patients On June 22, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The FDA approved the combination of two oral drugs called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist) for the treatment of advanced tumors […] June 28, 2022

National Brain Tumor Society Launches DNA Damage Response Consortium with Yale Consortium seeks to advance underdeveloped area of brain cancer research, advance drug development, and improve treatment options for patients Today, the National Brain Tumor Society (NBTS) announced the launch of its new flagship research initiative, the DNA Damage Response Consortium, in partnership with Yale Cancer Center. The consortium will bring together a diverse team of […] February 22, 2022

National Brain Tumor Society Statement on New Biden-Harris Cancer Moonshot Goals National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, research, information, and support, was honored to represent the millions of Americans impacted by brain tumors every year at a White House event to reignite the Cancer Moonshot.  The following is a statement from NBTS chief executive officer, David Arons, on today’s announcement. […] February 2, 2022

Widely-available Drug May Benefit Glioblastoma Treatment Based on data from NBTS’s Defeat GBM Research Collaborative and with support from the Sharpe family, Dr. Paul Mischel (Stanford University) and his laboratory team found that the antidepressant drug, fluoxetine (common brand name: Prozac), potently targets tumor metabolism and inhibits epidermal growth factor (EGFR) signaling, triggering the killing of glioblastoma (GBM) cells. Dr. Mischel’s […] December 17, 2021